Bandingkan kaedah
Semak kaedah pilihan anda secara bersebelahan; baris yang berbeza akan diserlahkan.
| Indeks Aktiviti Penyakit Spondilitis Ankilosis Mandi (BASDAI)× | Indeks Aktiviti Penyakit Lupus Eritematosus Sistemik 2000 (SLEDAI-2K)× | |
|---|---|---|
| Bidang | Reumatologi | Reumatologi |
| Keluarga | Process / pipeline | Process / pipeline |
| Tahun asal≠ | 1994 | 2002 |
| Pengasas≠ | Garrett et al. | Gladman et al. |
| Jenis≠ | Patient-reported outcome (PRO) | Clinician-rated |
| Sumber perintis≠ | Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. The Journal of Rheumatology. 1994;21(12):2286-2291. link ↗ | Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. The Journal of Rheumatology. 2002;29(2):288-291. link ↗ |
| Alias≠ | BASDAI, BAS-DAI | SLEDAI, SLEDAI-2K, SLE Disease Activity Index |
| Berkaitan≠ | 4 | 3 |
| Ringkasan≠ | The BASDAI is a patient-reported outcome measure of disease activity in ankylosing spondylitis (AS), a chronic inflammatory arthropathy affecting the spine and axial skeleton. Introduced by Garrett et al. in 1994, BASDAI uses six simple patient self-report items focused on the cardinal symptoms of AS: fatigue, spinal pain, peripheral joint involvement, and morning stiffness. As a PRO measure, BASDAI is practical for routine monitoring, responsive to treatment, and strongly associated with clinical outcomes and spinal damage progression, making it a cornerstone outcome in AS management and clinical trials. | The SLEDAI is a comprehensive clinician-assessed measure of systemic lupus erythematosus (SLE) disease activity, capturing manifestations across multiple organ systems (cutaneous, renal, neuropsychiatric, hematologic, and serological). Introduced by Bombardier et al. (1992) and refined as SLEDAI-2K by Gladman et al. (2002), SLEDAI uses weighted scoring of 24 clinical and laboratory features to quantify overall SLE activity. It is the most widely used outcome measure in SLE research and clinical trials, enabling standardised assessment of disease progression, flare prediction, and treatment response in this complex multisystem disease. |
| ScholarGateSet data ↗ |
|
|